Crick — Clinical Intelligence Platform

Not applicableEnrolling By InvitationNCT06314789

What this trial is testing

The Use of Lung Ultrasonography in the Delivery Room in Neonates

Who this might be right for

Suspected Damage to Fetus From Other Disease in the Mother, Affecting Management of Mother, With DeliveryPatient Death or Serious Disability Associated With A Haemolytic Reaction Due to the Administration of ABO-Incompatible Blood or Blood Products

Kırıkkale University 112

Results for “Hemolytic Disease of the Fetus and Newborn”

Characterize the Clinical Course of Pregnant Women and Children at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn

EPO-4-Rhesus Study

Application of Quantitative Hemorrhage Detection in Fetomaternal Hemorrhage Syndrome for the Diagnosis of Hemolytic Disease of the Newborn

Neonatal Cord Blood Screening for HDN

Study to Determine the Maximum Tolerated Dose, Safety and Effectiveness of Pomalidomide for Patients With Sickle Cell Disease

The Use of Lung Ultrasonography in the Delivery Room in Neonates

The Relevance Between the Level of Fetal Hemoglobin and Short-term Complications in Extremely Preterm Infants

Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)

Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease

Cord Blood S100B Protein Levels in Neonates Following Intrauterine Transfusions for HDFN-Associated Fetal Anemia

Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease

Hydroxyurea for the Treatment of Patients With Sickle Cell Anemia

Unraveling the Impact of Thalidomide at Diverse Doses in Transfusion Dependent Beta Thalassemia

Long Term Beta Thalassemia Treatment: Findings From The Extension Period

Effect of Broccoli Sprouts Homogenate on SS RBC

Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Pregnant Women at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn (HDFN)

Risk Factors and Clinical Outcomes of Neonatal Anemia in NICU

Hydroxyurea to Treat Beta-Thalassemia (Cooley's Anemia)

In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM)

Fetal Haemoglobin and Cerebral and Peripheral Oxygenation.